The Highest Leukaemia-Free Survival After Allogeneic Bone Marrow Transplantation is Seen in Patients with Grade I Acute Graft-Versus-Host Disease
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 24 (1-2) , 71-79
- https://doi.org/10.3109/10428199609045715
Abstract
The purpose of the present study was to evaluate the relation between the grade of acute graft-versus-host disease (GVHD) and several outcome parameters. Special attention was given to leukaemia-free survival (LFS). The study included 2,122 patients with acute leukaemia in first remission and 780 patients with chronic myeloid leukaemia (CML) in the first chronic phase, who were receiving first transplants from HLA-identical donors. Transplant-related mortality (TRM) was the same in patients with or without grade I acute GVHD, but was increased in patients with grades II, III and IV acute GVHD. In patients with grades 0, I, II, III and IV acute GVHD, the five-year probability of TRM overall was 20 1%, 19 2%, 30 2%, 61 4% and 90 3%, respectively. The incidence of relapse in patients with grades I-IV was lower than in patients without acute GVHD. The five-year relapse probability according to GVHD grade (0–IV), was 28 2%, 22 2%, 22 2%, 17 5% and 20 2%. The five-year LFS in all patients with leukaemia, according to grade of acute GVHD, was 57 2%, 63 2%, 55 3%, 32 4% and 8 3%. In multivariate analysis, adjustments for age, sex, diagnosis, interval from diagnosis to transplantation, T-cell depletion and year of transplantation were considered. Patients with grade I acute GVHD had the highest LFS (relative risk 0.84, p = 0.04 compared with those without acute GVHD).Keywords
This publication has 24 references indexed in Scilit:
- Increased risk of relapse in patients with chronic myelogenous leukemia given T‐cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft‐versus‐host diseaseEuropean Journal of Haematology, 1993
- T-cell depletion of HLA-identical transplants in leukemiaBlood, 1991
- Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia [published erratum appears in Blood 1989 Aug 15;74(3):1180]Blood, 1989
- Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trialBlood, 1989
- Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic PhaseAnnals of Internal Medicine, 1988
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft- versus-host diseaseBlood, 1985
- DEATH BY GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH HLA MISMATCH, HIGH RECIPIENT AGE, LOW MARROW CELL DOSE, AND SPLENECTOMYTransplantation, 1985
- Antileukemic Effect of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1981
- Bone-Marrow TransplantationNew England Journal of Medicine, 1975